Author

P. N. Harter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:mouse· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1

Frequent Co-Authors

D. E. Reuss· 2 shared D. Schrimpf· 2 shared D. Stichel· 2 shared D. Sturm· 2 shared G. Reifenberger· 2 shared L. Krskova· 2 shared L. Sevenich· 2 shared M. Sill· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. E. Reuss

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune CheckpointSensitivity in BRAFV600E-mutant Glioma

Y. L. Xing, D. Panovska, J.-W. Park, S. Grossauer, K. Koeck, B. Bui, E. Nasajpour, J. J. Nirschl, Z.-P. Feng, P. Cheung, P. Habib, R. Wei, J. Wang, W. Thomason, J. Xiu, , C. K. Petritsch

This study shows that BRAF/MEK inhibition induces cell state transitions in BRAFV600E-mutant gliomas, leading to PD-L1 upregulation and immune evasion, which can be overcome by combining with immune checkpoint inhibition.

bioRxiv · Feb 3, 2023Cancer Biology

AMP-kinase mediates adaptation of glioblastoma cells to conditions of the tumour microenvironment

N. I. Lorenz, B. Sauer, P. S. Zeiner, M. I. Strecker, A.-L. Luger, D. Schulte, M. Mittelbronn, T. Alekseeva, L. Sevenich, P. N. Harter, C. Münch, J. P. Steinbach, M. W. Ronellenfitsch

This study shows that AMPK is essential for glioblastoma cells to adapt to low energy conditions in the tumor microenvironment, with AMPK inhibition reducing tumor growth and mitochondrial function.

bioRxiv · Mar 25, 2022 · PreprintCancer Biology

Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis

F. Klemm, A. Schaeffer, A. Salamero-Boix, T. Alekseeva, M. Schulz, K. Niesel, R. R. Maas, M. Groth, B. T. Elie, R. L. Bowman, M. E. Hegi, R. T. Daniel, P. S. Zeiner, J. Zinke, P. N. Harter, , L. Sevenich

The paper shows that blocking CSF1R in brain metastases initially reduces tumor growth but is ineffective in established tumors due to compensatory macrophage activation, which is overcome by combining CSF1R and STAT5 inhibition.

bioRxiv · Jun 7, 2021Cancer Biology

Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial ependymoma

P. Sievers, S. C. Henneken, C. Blume, M. Sill, D. Schrimpf, D. Stichel, K. Okonechnikov, D. E. Reuss, J. Benzel, K. Maass, M. Kool, D. Sturm, P. Kohlhof-Meinecke, O. Cruz, M. Mariona Sunol, , Z

The paper identifies a novel subset of supratentorial ependymomas in children characterized by recurrent PLAGL1 fusions and distinct molecular features.

bioRxiv · Apr 23, 2021 · PreprintCancer Biology

A subset of pediatric thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR

P. Sievers, M. Sill, D. Schrimpf, D. Stichel, D. E. Reuss, D. Sturm, J. Hench, S. Frank, L. Krskova, A. Vicha, M. Zapotocky, B. Bison, P. N. Harter, M. Snuderl, C. M. Kramm, , F. Sahm

This study identifies a distinct subset of pediatric gliomas with EGFR alterations, H3K27me3 loss, and broad tumor localization, suggesting EGFR inhibition as a potential therapy.

bioRxiv · Aug 28, 2020Cancer Biology